1. Home
  2. MFIC vs PHAT Comparison

MFIC vs PHAT Comparison

Compare MFIC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MFIC
  • PHAT
  • Stock Information
  • Founded
  • MFIC 2004
  • PHAT 2018
  • Country
  • MFIC United States
  • PHAT United States
  • Employees
  • MFIC N/A
  • PHAT N/A
  • Industry
  • MFIC Finance/Investors Services
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • MFIC Finance
  • PHAT Health Care
  • Exchange
  • MFIC Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • MFIC 1.1B
  • PHAT 942.6M
  • IPO Year
  • MFIC 2004
  • PHAT 2019
  • Fundamental
  • Price
  • MFIC $11.98
  • PHAT $14.55
  • Analyst Decision
  • MFIC Buy
  • PHAT Strong Buy
  • Analyst Count
  • MFIC 7
  • PHAT 5
  • Target Price
  • MFIC $13.11
  • PHAT $17.60
  • AVG Volume (30 Days)
  • MFIC 475.9K
  • PHAT 977.8K
  • Earning Date
  • MFIC 11-06-2025
  • PHAT 10-30-2025
  • Dividend Yield
  • MFIC 12.70%
  • PHAT N/A
  • EPS Growth
  • MFIC N/A
  • PHAT N/A
  • EPS
  • MFIC 1.07
  • PHAT N/A
  • Revenue
  • MFIC $324,678,000.00
  • PHAT $147,190,000.00
  • Revenue This Year
  • MFIC $10.19
  • PHAT $218.38
  • Revenue Next Year
  • MFIC N/A
  • PHAT $87.14
  • P/E Ratio
  • MFIC $11.20
  • PHAT N/A
  • Revenue Growth
  • MFIC 16.80
  • PHAT 460.30
  • 52 Week Low
  • MFIC $10.18
  • PHAT $2.21
  • 52 Week High
  • MFIC $14.74
  • PHAT $16.08
  • Technical
  • Relative Strength Index (RSI)
  • MFIC 46.93
  • PHAT 63.09
  • Support Level
  • MFIC $11.88
  • PHAT $13.79
  • Resistance Level
  • MFIC $12.14
  • PHAT $14.22
  • Average True Range (ATR)
  • MFIC 0.24
  • PHAT 1.04
  • MACD
  • MFIC -0.01
  • PHAT 0.07
  • Stochastic Oscillator
  • MFIC 28.08
  • PHAT 58.36

About MFIC MidCap Financial Investment Corporation

MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: